Dermata Therapeutics (DRMAW) Competitors $0.02 +0.00 (+3.14%) As of 09:46 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsSEC FilingsTrendsBuy This Stock DRMAW vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ARAV, ACABW, BFRIW, BTMDW, and BCTXWShould you be buying Dermata Therapeutics stock or one of its competitors? The main competitors of Dermata Therapeutics include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), ARAVIVE (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), and BriaCell Therapeutics (BCTXW). These companies are all part of the "pharmaceutical products" industry. Dermata Therapeutics vs. Its Competitors 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Alvotech ARAVIVE Atlantic Coastal Acquisition Corp. II Biofrontera biote BriaCell Therapeutics 180 Life Sciences (NASDAQ:ATNFW) and Dermata Therapeutics (NASDAQ:DRMAW) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends. Is ATNFW or DRMAW more profitable? Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A N/A N/A Dermata Therapeutics N/A N/A N/A Does the media refer more to ATNFW or DRMAW? In the previous week, 180 Life Sciences had 4 more articles in the media than Dermata Therapeutics. MarketBeat recorded 5 mentions for 180 Life Sciences and 1 mentions for Dermata Therapeutics. Dermata Therapeutics' average media sentiment score of 1.87 beat 180 Life Sciences' score of 1.01 indicating that Dermata Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment 180 Life Sciences Positive Dermata Therapeutics Very Positive Which has stronger earnings & valuation, ATNFW or DRMAW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/AN/AN/AN/ADermata TherapeuticsN/AN/AN/AN/AN/A Summary180 Life Sciences and Dermata Therapeutics tied by winning 1 of the 2 factors compared between the two stocks. Get Dermata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DRMAW and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRMAW vs. The Competition Export to ExcelMetricDermata TherapeuticsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$138.49M$5.68B$9.81BDividend YieldN/A3.74%4.61%4.07%P/E RatioN/A3.8230.6825.56Price / SalesN/A4,350.19464.10116.64Price / CashN/A13.1938.2159.48Price / BookN/A45.658.996.13Net IncomeN/A-$90.99M$3.25B$264.89M7 Day PerformanceN/A1.49%4.78%2.67%1 Month PerformanceN/A4.99%6.80%3.11%1 Year PerformanceN/A184.07%30.61%25.14% Dermata Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRMAWDermata TherapeuticsN/A$0.02+3.1%N/A+27.7%$0.00N/A0.008Positive NewsGap DownATNFW180 Life SciencesN/A$0.01-5.7%N/A+4,239.6%$0.00N/A0.007News CoverageHigh Trading VolumeLBPSW4D pharmaN/AN/AN/AN/A$0.00$522K0.00N/AAEHAWAesther Healthcare AcquisitionN/A$0.01+84.9%N/AN/A$0.00N/A0.002AIMDWAinosN/A$0.25-29.1%N/AN/A$0.00$106.21K0.0040ALVOWAlvotechN/A$1.27-3.1%N/A-52.4%$0.00$585.60M0.004Gap UpARAVARAVIVEN/A$0.04flatN/AN/A$0.00$9.14M0.0020High Trading VolumeACABWAtlantic Coastal Acquisition Corp. IIN/A$0.05+2.9%N/AN/A$0.00N/A0.0015BFRIWBiofronteraN/A$0.14-9.9%N/AN/A$0.00$38.00M0.0070BTMDWbioteN/A$0.02flatN/AN/A$0.00$199.38M0.00N/AGap UpBCTXWBriaCell TherapeuticsN/A$0.03-6.2%N/A-85.8%$0.00N/A0.008Short Interest ↓Gap DownHigh Trading Volume Related Companies and Tools Related Companies ATNFW Competitors LBPSW Competitors AEHAW Competitors AIMDW Competitors ALVOW Competitors ARAV Competitors ACABW Competitors BFRIW Competitors BTMDW Competitors BCTXW Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DRMAW) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dermata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dermata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access